A review of emerging factor XI inhibitors

References

• Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Thromb Res. 2014;134(5):931–938.
   PubMedGoogle Scholar
• Gale AJ. Current understanding of hemostasis. Toxicol Pathol. 2011;39:273.
   PubMed Web of Science ®Google Scholar
• Umerah CO, II M. Anticoagulation. decision-making in orthopedic and regional anesthesiology: a case-based approach [Internet]. 2022 [cited 2022 Aug 6];47–52. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560651/.
   Google Scholar
• LaPelusa A, Dave HD. Physiology, Hemostasis. StatPearls [Internet]. 2022 [cited 2022 Aug 5]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK545263/.
   Google Scholar
• Solari F, Varacallo M. Low molecular weight heparin (LMWH). StatPearls [Internet]. 2022 [cited 2022 Aug 6]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK525957/.
   Google Scholar
• Levine M, Gresham C, Ruha A-M. Toxicology case files case files of the medical toxicology fellowship at banner good Samaritan Medical Center in phoenix, AZ: a non-warfarin anticoagulant overdose CASE PRESENTATION. J Med Toxical. 2009;5.
   Google Scholar
• Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. Ann Emerg Med. 2020;76:470–485.
   PubMed Web of Science ®Google Scholar
• Harter K, Levine M, Henderson S. Anticoagulation Drug Therapy: a Review. West J Emerg Med. 2015;16:11–17.
   PubMed Web of Science ®Google Scholar
• Georgi B, Mielke J, Chaffin M, et al. Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI. Stroke. 2019;50:3004–3012.
   PubMed Web of Science ®Google Scholar
• Fredenburgh JC, Weitz JI. Factor XI as a target for new anticoagulants. Hamostaseologie. 2021;41:104–110.
   PubMedGoogle Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM, et al. international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;2022(23):e334–e347.
   Google Scholar
• Weitz JI, Haas S, Ageno W, et al. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. J Thromb Thrombolysis. 2020;50:267–277.
   PubMedGoogle Scholar
• Cheung CYS, Parikh J, Farrell A, et al. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes. Ann Pharmacother. 2021;55:711–722.
   PubMedGoogle Scholar
• Kuno T, Takagi H, Ando T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term dialysis. J Am Coll Cardiol. 2020;75:273–285.
   PubMed Web of Science ®Google Scholar
• Székely O, Borgi M, Lip GYH. Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation. Expert Opin Emerg Drugs.2019;24(1):55–61.
   Google Scholar
• Franchini M, Liumbruno GM, Bonfanti C, et al. The evolution of anticoagulant therapy. Blood Transfus. 2016;14:175–184.
   PubMed Web of Science ®Google Scholar
• Chen A, Stecker E, Warden B A. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13): 1–18 .
   Web of Science ®Google Scholar
• Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003;17:S1–S5.
   PubMedGoogle Scholar
• Ho KM, Pavey W. Applying the cell-based coagulation model in the management of critical bleeding. Anaesth Intensive Care. 2017;45:166–176.
   PubMed Web of Science ®Google Scholar
• Fredenburgh JC, Weitz JI. Factor XI as a target for new anticoagulants. hamostaseologie [Internet]. 2021 [cited 2022 Aug 9];41:104–110. Available from: https://pubmed.ncbi.nlm.nih.gov/33860518/.
   Google Scholar
• Key NS. Epidemiologic and clinical data linking factors XI and XII to thrombosis. Hematology. 2014;2014:66–70.
   PubMedGoogle Scholar
• Puy C, Rigg RA, McCarty OJT. The hemostatic role of factor XI. Thromb Res. 2016;141:S8–S11.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PHB, Novel A. Assay for determining bleeding risk in factor XI deficiency. Thromb Haemost [Internet]. 2021 [cited 2022 Nov 13];121:121
   Google Scholar
• Sharman Moser S, Chodick G, Ni YG, et al. The association between factor XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events. Thromb Haemost. 2022;122:808–817.
   PubMedGoogle Scholar
• Zadra G, Asselta R, Tenchini ML, et al. Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians. Haematologica. 2008;93:715–721.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European network of rare bleeding disorders. J Thromb Haemost. 2012;10:615–621.
   PubMed Web of Science ®Google Scholar
• Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deficiency on ferric chloride‐induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3:695–702.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Fredenburgh JC. Factors XI and XII as targets for new anticoagulants. Front Med (Lausanne). 2017;4:19.
   PubMed Web of Science ®Google Scholar
• Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20:491–495.
   PubMed Web of Science ®Google Scholar
• Koch AW, Schiering N, Melkko S, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019;133:1507–1516.
   PubMed Web of Science ®Google Scholar
• Yi BA, Freedholm D, Widener N, et al. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of factor XI and Factor XIa. J Thromb Haemost. 2022;20:307–315.
   PubMed Web of Science ®Google Scholar
• Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385:609–617.
   PubMed Web of Science ®Google Scholar
• Thomas D, Thelen K, Kraff S, et al. BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics. Res Pract Thromb Haemost. 2019;3:242–253.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323:130–139.
   PubMed Web of Science ®Google Scholar
• Nowotny B, Thomas D, Schwers S, et al. First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men. J Thromb Haemost. 2022;20:1684–1695.
   PubMedGoogle Scholar
• Lorentz CU, Verbout NG, Wallisch M, et al. Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial. Arterioscler Thromb Vasc Biol. 2019;39:799–809.
   PubMed Web of Science ®Google Scholar
• Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138:2173–2184.
   PubMed Web of Science ®Google Scholar
• Thomas D, Kanefendt F, Schwers S, et al. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost. 2021;19:2407–2416.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399:1383–1390.
   PubMed Web of Science ®Google Scholar
• Rao SV, Kirsch B, DL B, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor xia inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022;146:1196–1206.
   PubMed Web of Science ®Google Scholar
• Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022;400:997–1007.
   PubMed Web of Science ®Google Scholar
• Perera V, Wang Z, Luettgen J, et al. First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022;15:330–342.
   PubMedGoogle Scholar
• Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of milvexian in participants with mild or moderate hepatic impairment compared with healthy participants. Clin Pharmacokinet. 2022;61:857–867.
   PubMed Web of Science ®Google Scholar
• Perera V, Wang Z, Lubin S, et al. Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of milvexian, a factor xia inhibitor. Cardiol Ther. 2022;11:407–419.
   PubMedGoogle Scholar
• Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385:2161–2172.
   PubMed Web of Science ®Google Scholar
• Kumbhani DJ. Antithrombotic treatment with factor xia inhibition to optimize management of acute thromboembolic events for secondary stroke prevention - AXIOMATIC-SSP [Internet]. [cited 2022 Nov 2]. Available from: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/08/27/04/12/AXIOMATIC-SSP.
   Google Scholar
• Crooke ST, Liang X-H, Baker BF, et al. Antisense technology: a review. J Biol Chem. 2021;296:100416.
   PubMed Web of Science ®Google Scholar
• Liu Q, Bethune C, Dessouki E, et al. ISIS-FXIRx, A novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers. Blood. 2011;118: 209–209.
   Google Scholar
• Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232–240.
   PubMed Web of Science ®Google Scholar
• Walsh M, Bethune C, Smyth A, et al. Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD. Kidney Int Rep. 2022;7:200–209.
   PubMedGoogle Scholar
• Willmann S, Marostica E, Snelder N, et al. PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients. CPT Pharmacometrics Syst Pharmacol. 2021;10:890–901.
   PubMedGoogle Scholar
• Pharmaceuticals I. Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment [Internet]. [cited 2023 Feb 12]. Available from: https://www.prnewswire.com/news-releases/ionis-announces-positive-topline-results-from-phase-2b-clinical-study-of-fesomersen-a-potential-novel-anti-thrombotic-treatment-301594902.html.
   Google Scholar